Loading…
← CockpitCompetitor Analysis › 4519.T Chugai Pharmaceutical CoOpen in the cockpit ↗

Chugai Pharmaceutical Co4519.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Pharmaceuticals: Major

Japanese biopharma majority-owned by Roche, developing antibody drugs for cancer, immunology and rare disease.

≈ Roche's Japan-based GenentechMomentum strong 69
Mkt cap
$75.2B
US dollars, full cap
Free float
37%
of shares outstanding
$/day
$145M
20-day average traded
Fwd P/E
23.7×
forward earnings
ROIC−WACC
+32.4 pp
WACC 7.2%
Hurdle
-5 pp
Req g minus delivered
Next earnings
78 days
4 Feb 2027
Close · JPY¥7,206
1D-1.8%
1W+0.8%
1M+13.8%
3M+3.9%
6M-8.4%
YTD-11.8%
1Y+6.5%
ATR %3.0%
52w lowhigh32.0% off high

What Chugai Pharmaceutical does

Japanese biopharma majority-owned by Roche, developing antibody drugs for cancer, immunology and rare disease.

Roche owns a majority and sells Chugai-discovered antibodies such as Actemra and Hemlibra outside Japan, paying Chugai for supply and royalties, so a large share of income comes from Roche. In Japan Chugai sells those drugs and Roche's own products itself. It has kept its listing and independence since the 2002 tie-up.

In one line: Roche's Japan-based Genentech.

Products and services

  • Actemra/RoActemra (anti-IL-6)
  • Hemlibra (hemophilia A)
  • Oncology antibody pipeline
  • Enspryng & other specialty drugs

Customers

  • Hospitals & specialists in oncology, immunology, h

Where it sits in the supply chain

  • Healthcare
  • Biopharmaceuticals
  • Antibody drug discovery & development

What could go right

  • Global Roche partnership royalties
  • New antibody drug approvals

What could go wrong

  • Patent cliffs on older drugs
  • Drug pricing pressure in Japan

Moat: narrow (IP / patents, process know-how). Roche alliance funds R&D and gives global commercial reach for Chugai-discovered antibodies.

Headquarters: Tokyo, Japan · Founded: 1925 · Employees: 7,872

Named competitors

Chugai Pharmaceutical at a glance

Size Chugai Pharmaceutical (4519.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $75.2B, the 19th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥7,206 on 18 Nov 2026.

Performance Over six months the shares fell 8.4%, against +14.7% for the median peer and -1.4% for the Japan market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue grew 16.5% over the last twelve months (peer median +6.1%); the operating margin is 49.8% (peer median 24.0%).

Valuation It trades at 23.7× forward earnings against a peer median of 16.9× (8th most expensive of 21).

Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -5 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 32.4 points above its cost of capital (7.2% WACC).

Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 1154519.T 92
Six months, rebased to 100: Chugai Pharmaceutical against the median of its 20 peers (local-currency closes).

Chugai Pharmaceutical financials

Reported figures in JPY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥1.41T¥1.26T¥1.17T¥1.11T¥1.26T
Revenue growth—+7%+5%-12%—
Gross profit¥1.01T¥894B¥831B¥693B¥783B
EBITDA¥745B¥624B¥576B¥447B¥565B
Net income¥504B¥434B¥387B¥325B¥374B
Free cash flow¥367B¥313B¥399B¥339B¥182B
Capital expenditure¥103B¥112B¥54.9B¥74.3B¥71.2B
Total debt¥16.1B¥25.7B¥10.9B¥13.5B¥14.1B

Quarterly statements and history in the cockpit →

Chugai Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%0%+10%MRK4502603259BAYNREGNGSKGALDSANSUNPHARMABMY600276688235SDZVRTX4578HLNRPRXBIIBPFEZTS4519.T6-month return →1-month return →
Up and to the right = strong over both horizons. Chugai Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×40×MRK4502603259BAYNREGNGSKGALDSANSUNPHARMABMY600276688235SDZVRTX4578RPRXPFE4519.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Chugai Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+25%+50%+75%0%50%MRK4502603259REGNGSKGALDSANSUNPHARMABMY6002766882354519.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Chugai Pharmaceutical is the large dot.

Chugai Pharmaceutical competitors and peer comparison

Head to head with its named competitors (4519.T vs 4502.T vs 4568.T vs 4503.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Chugai Pharmaceutical 4519.T$75.2B-8%+17%50%23.7×5.0%
Takeda Pharmaceutical 4502.T$69.8B+30%+6%18%51.0×3.7%
Daiichi Sankyo 4568.T$31.4B+8%+17%13%18.4×7.6%
Astellas Pharma 4503.T$31.4B+17%+19%23%12.9×-9.0%
Roche RO.SW$381B+21%-1%31%19.9×1.7%
Regeneron Pharmaceuticals REGN$97.8B+46%+19%30%11.8×-1.1%

How Chugai Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Chugai Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure4519.TPeer medianRank in peer set
1-month return+13.8%+4.3%4th highest of 21
6-month return-8.4%+14.7%2nd lowest of 21
Distance from 52-week high-32.0%-5.9%2nd lowest of 21
Revenue growth (TTM)+16.5%+6.1%4th highest of 21
Operating margin49.8%24.0%2nd highest of 21
Forward P/E23.7×16.9×8th most expensive of 21
Growth the price implies (Req g, 7 yrs)5.0%6.2%9th least demanding of 20
Growth delivered (Del g)+9.8%+6.4%7th highest of 20
Hurdle (Req g minus delivered)-4.8 pp-3.4 pp10th least demanding of 20
ROIC minus cost of capital+32.4 pp+4.4 pp2nd highest of 21
EV / EBITDA14.9×11.6×9th most expensive of 19
Net debt / EBITDA-1.1×1.8×4th least indebted of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Chugai Pharmaceutical 4519.TJapan$75.2B-8%+17%50%23.7×5.0%+9.8%
Merck KGaA MRK.DEGermany$71.3B+16%+1%19%17.4×7.4%+3.8%
Takeda Pharmaceutical 4502.TJapan$69.8B+30%+6%18%51.0×3.7%+7.1%
WuXi AppTec 603259.SSChina$64.2B+40%+32%43%17.0×7.2%+22.3%
Bayer BAYN.DEGermany$60.3B+48%0%13%12.3×n/an/a
Regeneron Pharmaceuticals REGNUnited States$97.8B+46%+19%30%11.8×-1.1%+11.0%
GSK GSK.LUnited Kingdom$97.9B-3%+4%25%10.4×-0.1%-0.9%
Galderma GALD.SWSwitzerland$51.9B+18%+16%19%45.7×18.0%+6.4%
Sanofi SAN.PAFrance$114B+13%+15%27%9.7×-4.8%+3.9%
Sun Pharmaceutical Industries SUNPHARMA.NSIndia$48.0B-1%+12%23%36.0×28.7%+11.7%
Bristol Myers Squibb BMYUnited States$122B+3%+4%33%9.2×-13.1%+2.5%
Jiangsu Hengrui Pharmaceuticals 600276.SSChina$45.7B-13%+6%27%33.4×13.4%+2.7%
BeOne Medicines 688235.SSChina$45.5B+9%+25%18%59.7×19.1%+79.3%
Sandoz SDZ.SWSwitzerland$41.7B+26%+1%15%24.5×7.5%+0.4%
Vertex Pharmaceuticals VRTXUnited States$136B+25%+11%35%28.5×6.2%+14.2%
Otsuka Hldgs 4578.TJapan$39.9B+9%+11%18%16.8×1.6%+11.7%
Haleon HLN.LUnited Kingdom$39.6B0%+1%23%16.4×5.2%+2.2%
Royalty Pharma RPRXUnited States$39.4B+29%+11%66%11.5×10.8%+2.3%
Biogen BIIBUnited States$37.2B+34%+2%17%17.1×10.1%-5.1%
Pfizer PFEUnited States$160B+9%+1%26%9.9×-4.3%+8.5%
Zoetis ZTSUnited States$34.8B+7%+1%37%13.8×-2.9%+7.2%

Questions

Who are Chugai Pharmaceutical's main competitors?
Named competitors: Takeda (4502.T), Daiichi Sankyo (4568.T), Astellas (4503.T), Roche (RO.SW), Regeneron (REGN). The cockpit's measured peer set (industry) also includes Merck KGaA (MRK.DE), Takeda Pharmaceutical (4502.T), WuXi AppTec (603259.SS), Bayer (BAYN.DE), Regeneron Pharmaceuticals (REGN), GSK (GSK.L).
Is Chugai Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 23.7× against a peer median of 16.9×, 8th most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -5 pp: the price already allows for a slowdown.
How has Chugai Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -8.4% against +14.7% for the median peer; over one year +6.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.